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Abstract
Background: Hepatocellular carcinoma (HCC) is a lethal disease, while the precise underlying molecular mechanisms of
HCC pathogenesis remain to be defined. MicroRNA (miRNA), a class of non-coding small RNAs, can post-transcriptionally
regulate gene expression. Altered miRNA expression has been reported in HCCs. This study assessed expression and the
oncogenic activity of miRNA-10b (miR-10b) in HCC.
Methods: Forty-five paired human HCC and adjacent non-tumor tissues were collected for qRT-PCR and
immunohistochemistry analysis of miR-10b and CUB and Sushi multiple domains 1 (CSMD1), respectively. We analyzed
the clinicopathological data from these patients to further determine if there was an association between miR-10b and
CSMD1. HCC cell lines were used to assess the effects of miR-10b mimics or inhibitors on cell viability, migration, invasion,
cell cycle distribution, and colony formation. Luciferase assay was used to assess miR-10b binding to the 3’-untranslated
region (3’-UTR) of CSMD1.
Results: miR-10b was highly expressed in HCC tissues compared to normal tissues. In vitro, overexpression of miR-10b
enhanced HCC cell viability, migration, and invasion; whereas, downregulation of miR-10b expression suppressed these
properties in HCC cells. Injection of miR-10b mimics into tumor cell xenografts also promoted xenograft growth in
nude mice. Bioinformatics and luciferase reporter assay demonstrated that CSMD1 was the target gene of miR-10b.
Immunocytochemical, immunohistochemical, and qRT-PCR data indicated that miR-10b decreased CSMD1 expression
in HCC cells.
Conclusions: We showed that miR-10b is overexpressed in HCC tissues and miR-10b mimics promoted HCC cell
viability and invasion via targeting CSMD1 expression. Our findings suggest that miR-10b acts as an oncogene by
targeting the tumor suppressor gene, CSMD1, in HCC.
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Background
Hepatocellular carcinoma (HCC) is a significant health
problem, contributing to more than 600,000 cancer-
related deaths globally each year. Of note, approximately
half of these cases occur in China [1]. The major risk
factors for HCC are hepatitis B or C virus (HBV and
HCV) infection and consumption of alcohol or aflatoxin
B1-contaminated food products [2]. Because HCC
patients are typcially only diagnosed at advanced stages,
surgical therapies are often not an option. Moreover,
chemotherapy and radiotherapy are generally ineffective
for these patients [3]. However, sorafenib, a multiple
tyrosine kinase inhibitor, is the only drug that has dem-
onstrated survival benefits in patients with advanced
HCC [4]. While liver transplantation could help HCC
patients live longer, the availability of organ donors is a
limiting factor. Thus, there is an urgent need to better
understand the biology and pathogenesis of HCC for
developing novel strategies that allow effective control,
prevention, or prediction of treatment responses of this
deadly disease.
MicroRNAs (miRNAs) are a class of small endogenous
non-coding RNAs that play roles in regulating cell
growth, differentiation, embryonic development, and
disease progression. At the molecular level, miRNA can
directly bind to the 3’-untranslated region (3’-UTR) of
their target mRNAs to degrade them and/or repress their
translation [5, 6]. Accumulating evidence indicates that
miRNA expression is remarkably dysregulated in different
human cancers and that miRNAs can act as oncogenes or
tumor suppressor genes to regulate tumorigenesis, progres-
sion, and metastasis [7–9]. Among them, miRNA-10b
(miR-10b) has been reported to be highly expressed in
many types of human cancers, such as breast, pancreatic,
and nasopharyngeal cancers, malignant glioma, and HCC
[10–14]. A previous study using Agilent human miRNA
microarray detected significant upregulation of miR-10b in
HCC tissues [15]. In this study, we assessed miR-10b ex-
pression in HCC and then investigated its oncogenic activ-
ity and the underlying molecular mechanisms in HCC cells.
Methods
Tissue samples and cell lines
A total of 45 paired human HCC and adjacent non-tumor
liver tissues (37 males and 8 females with an average age
of 51 years; 40 were HBsAg (+), 24 AFP > 400 ng/mL, 31
had a tumor size ≥ 5 cm) were collected from Tangdu
Hospital, The Fourth Military Medical University (Xi’an,
China). Surgically resected tissue samples, including HCC
with or without liver cirrhosis, were fixed in 10 % buffered
formalin and embedded in paraffin. Each case was exam-
ined and diagnosed by three pathologists according to the
morphological criteria of liver cirrhosis and HCC. HCC
samples were graded according to Edmondson’s criteria.
None of the patients had received any other therapies
such as chemoembolization or chemotherapy before sur-
gery. In this study, we obtained paraffin blocks from each
patient and isolated total cellular RNA for detection of
miR-10b expression.
The human HCC cell line, HepG2, and a normal human
hepatocyte line, HL-7702, were cultured in Dulbecco’s
modified Eagle’s medium (DMEM, HyClone, Logan, UT,
USA) or RPMI 1640 medium (HyClone) containing 10 %
fetal bovine serum (Invitrogen, Carlsbad, CA, USA) at 37 °
C in a humidified chamber supplemented with 5 % CO2.
Quantitative RT-PCR
Total cellular RNA was isolated from tissues and cells
using a miREeasy FFPE kit (Qiagen, Hilden, Germany)
and the RNAsimple Total RNA Kit (Tiangen, Beijing,
China) according to the manufacturers’ protocols. Next,
these RNA samples were amplified using an ABI 7500
fast Real-Time PCR system (ABI, Foster city, CA, USA)
and U6 RNA was used as an internal control for miR-
10b expression. The PCR amplification conditions were
95 °C for 15 min and then 40 cycles of 94 °C for 15 s,
60 °C for 30 s, and 70 °C for 35 s. For detection of
CSMD1 mRNA levels, aliquots of 1 μg of total RNA
samples were reversely transcribed into cDNA using the
miScriptII RT Kit from Qiagen and subjected to qPCR
amplification of CSMD1 mRNA. CSMD1 primers used
were 5’-TCCAGTCATTACCACGGCAC-3’ and 5’-CAT
GCCCAGCATAGCCATTC-3’. GAPDH was used as an
internal control, using primers 5’-GCACCGTCAA
GGCTGAGAAC-3’ and 5’-TGGTGAAGACGCCAG
TGGA-3’.
Plasmid construction and luciferase reporter assay
The pmiR-RB-REPORT™ luciferase vector (Riobobio,
Guangzhou, China) was used to construct the pMIR-
CSMD1 or pMIR-CSMD1-mut vectors. HepG2 cells
were cultured in 24-well plates and transiently trans-
fected with 100 ng pMIR-CSMD1 or pMIR-CSMD1-mut
vector and 50 pmol hsa-miR-10b mimics (10b-m) or
mimics negative control (mnc) using Lipofectamine
2000 (Invitrogen). 10b-m and mnc were purchased from
GenePharma (Shanghai, China). Luciferase activity was
measured after 48 h using the Dual Luciferase Reporter
Assay kit (Promega, Madison, WI, USA) according to
the manufacturer’s instructions.
Gene transfection
10b-m, mnc, Hsa-miR-10b inhibitors (10b-i), inhibitors
negative control (inc) as well as CSMD1 siRNA were ob-
tained from GenePharma (Shanghai, China). HepG2 cells
were cultured in antibiotic-free medium and grown over-
night and then transfected with 10b-m, mnc, 10b-i, inc, or
CSMD1 siRNA using Lipofectamine 2000 (Invitrogen,
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Carlsbad, CA, USA) according to the manufacturer’s
instructions. The CSMD1 siRNA sequences were 5’-CC
AUAUGGCUAACUGGCAUTT -3’ and 5’-AUGCCAG
UUAGCCAUAUGGTT -3’.
Cell viability assay
Cell viability was assessed using the 3-(4,5-dimethylthi
azol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
Briefly, cells were seeded into 96-well plates and grown
overnight, and then transfected with 10b-m or negative
control (NC) using Lipofectamine 2000 (Invitrogen) for
up to 4 days. At the end of each experiment, 20 μl MTT
was added into each well and cells were incubated for 4 h
at 37 °C. Next, 150 μl dimethyl sulfoxide (DMSO) was
added to dissolve the purple precipitate. The optical ab-
sorbance of each sample was recorded at 490 nm using
PowerWave XS machine (BioTek, Vermont, USA).
Tumor cell invasion and migration assay
Tumor cell migration and invasion were assayed using
Transwell chambers (8 μm; Corning, Corning, NY, USA)
and Matrigel (BD Biosciences, San Jose, CA, USA). In
particular, 24 h-transiently transfected HepG2 cells were
suspended in serum-free medium at a density of 6 × 104
cells, and 200 μl of the cell suspension were added into
the upper chamber, while 500 μl of DMEM containing
10 % FBS was added to the bottom chambers. The plates
were cultured for 24 h and the cells on the upper face of
the filters were removed with a cotton swab. The
migrated or invaded cells on the bottom side of the fil-
ters were fixed with 75 % ethanol and stained with 0.5 %
crystal violet for 10 min. For the invasion assay, the
filters were precoated with 5 μg/ml Matrigel (BD
Biosciences).
Wound scratch assay
HepG2 cells were seeded and transiently transfected
with miR-10b or NC for 24 h. After cells reached ap-
proximately 100 % confluency, a linear wound was made
across the confluent cell layer using 200 μl pipette tips.
Cells were then washed twice with phosphate buffered
saline (PBS) to remove cell debris and further cultured
for 24 h. During the cell culture, wound healing was
recorded under an inverted microscope.
Colony formation assay
HepG2 cells were seeded and transiently transfected
with miR-10b or NC for 24 h. 200 cells were then seeded
into 60 mm dishes and grown for 2 weeks. Cell colonies
were subsequently stained with Giemsa dye. For the soft
agar colony formation assay, 5 % agar and complete
medium in a 1:9 ratio were mixed at 50 °C, and 0.8 ml
was added into each well of a 24-well plate. After the
agar was completely solidified at room temperature,
0.8 ml of 0.3 % agar medium containing 40 cells was
added to each well covered with solidified agar. After the
agar solidified, 0.5 ml DMEM with 10 % FBS was added
into each well and the plate was placed in the incubator
for 3 weeks during which time the DMEM was replen-
ished twice per week.
Flow cytometry apoptosis and cell cycle assay
HepG2 cells were seeded and transiently transfected
with miR-10b or NC for 24 h. For flow cytometry, cells
were collected and stained with the Annexin V-PE/7-
AAD apoptosis detection kit (KeyGEN, Nanjing, China)
or cell cycle detection kit (KeyGEN) according to the man-
ufacturer’s instructions. Each sample containing 3 × 105
cells was measured by a flow cytometer (Beckman-Coulter,
Indianapolis, IN, USA).
Immunocytochemistry and immunohistochemistry
Immunostaining was carried out using a Streptavidin-
labeled peroxidase (S-P) kit (MaiXin Fuzhou, China)
according to the manufacturer’s instructions. The pri-
mary antibody used was a polyclonal rabbit anti-human
CSMD1 antibody at a dilution of 1:200 (Boaosen Ltd.
Company, Beijing, China). All of the immunostaining re-
agents were supplied by MaiXin Biotechnology Corpor-
ation Limited (Fuzhou, China). Positive immunostaining
with the anti-CSMD1 antibody was assessed when
granular brown color was observed in the cytoplasm.
Tumor cell xenograft assay in nude mice
HepG2 cells at 1 × 106 combined with 200 μl of serum-
free DMEM were injected into each nude mouse in the
flank region. Following 2 weeks, 50 μl miR-10b mimics or
negative control (NC) were injected into the tumor lesion
every 3 days (Riobobio, Guangzhou, China). Tumor
growth was measured using a caliper every other day, and
tumor volume was calculated according to the formula:
volume = length × width2 × 0.5. Finally, mice were sacri-
ficed and tumor mass was harvested for examination. All
studies were performed according to the Chinese Associ-
ation for the Accreditation of Laboratory Animal Care
guidelines for humane treatment of animals and adhered
to national and international standards.
Statistical analysis
All data are expressed as mean ± SD of at least three
separate experiments. Differences between groups were
analyzed using the paired t-test for normal distribution
by the F test. All statistical analyses were performed
using SPSS 19.0 software (Chicago, IL, USA). A p value ≤
0.05 was considered statistically significant.
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Results
Overexpression of miR-10b in HCC tissues and hepatoma
cell lines
To investigate the role of miR-10b in HCC, we first
assessed the expression level of miR-10b in 45 primary
HCC and adjacent matched tissues. The results dem-
onstrated that the expression level of miR-10b was
higher in HCC samples compared to adjacent non-
tumor tissue samples (−1.4590 ± 0.69542 vs. -1.7312 ±
0.62758, p < 0.01; Fig. 1a). Similarly, miR-10b expres-
sion was nearly 3-fold higher in HepG2 cells com-
pared to HL-7702 cells (Fig. 1b). These data indicate
that miR-10b expression is elevated in HCC.
miR-10b enhances HCC cell viability and colony formation
but reduces apoptosis
In HCC cell lines, miR-10b expression was almost 3-
fold higher in HepG2 cells compared to HL-7702 cells.
To test the oncogenic activity of miR-10b in HCC, we
transfected hsa-miR-10b mimics (10b-m), mimics nega-
tive control (mnc), hsa-miR-10b inhibitors (10b-i), or
inhibitors negative control (inc) into HepG2 cells
(Fig. 2). The miR-10b-mediated growth response was
evaluated by the MTT assay. As shown in Fig. 3a, miR-
10b mimics increased cell viability after 24–72 h trans-
fection. In contrast, miR-10b inhibition reduced cell
viability. The effect of miR-10b on cell clonogenic abil-
ity was assessed using the colony formation and soft
agar colony formation assays. The results showed that
the miR-10b inhibitor reduced the rate of colony for-
mation by 17.5 and 4.25 % respectively in colony for-
mation and soft agar colony formation assays (p < 0.01,
Fig. 3b). Furthermore, flow cytometry was used to
analyze cell cycle distribution. 19.3 % of miR-10b
mimic-transfected cells were in the S phase of the cell
cycle, compared to only 8.02 % of negative control cells
(p < 0.01, Fig. 3c). As shown in Fig. 3d, miR-10b trans-
fected cells exhibited lower rates of apoptosis (0.48 % of
early apoptotic cells and 0.27 % of late apoptotic cells)
compared to their negative control transfected counter-
parts (1.24 % of early apoptotic cells, 1.24 and 0.91 % of
late apoptotic cells; p < 0.01).
Fig. 2 Detection of transient transfection efficiency. We transfected
hsa-miR-10b mimics (10b-m), mimics negative control (mnc), hsa-miR-
10b inhibitors (10b-i), or inhibitors negative control (inc) into HepG2
cells. Relative levels of miR-10b were measured using qRT-PCR. After
transfection of 10b-m, the expression of mir-10b was significantly
increased, whereas 10b-i elicited the opposite result
Fig. 1 Overexpression of miR-10b in HCC tissues and cells. a Relative levels of miR-10b expression in HCC tissues (n = 45) and normal liver tissue
(n = 45) were measured using qRT-PCR. miR-10b levels were higher in HCC samples compared to adjacent nontumor tissues (−1.4590 ± 0.69542
vs. -1.7312 ± 0.62758, p < 0.01). b The relative levels of miR-10b expression in normal human hepatocytes and HepG2 cells were measured using
qRT-PCR. miR-10b expression was nearly 3-fold higher in HepG2 compared to HL-7702 cells
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miR-10b promotes HCC cell migration and invasion
Next, we assessed the effects of miR-10b on cell mi-
gration and invasion in HepG2 cells by overexpressing
miR-10b mimics, and using inhibitors of miR-10b as
well as their respective negative controls. We found
that miR-10b mimics led to a 2-fold increase in cell
migration and over 50 % increase in cell invasion
capacity. In contrast, tumor cell migration and inva-
sion were reduced by 40 %, respectively (p < 0.01,
Fig. 4a-b), after knockdown of miR-10b expression. In
addition, the wound healing ability of cells overex-
pressing miR-10b was significantly higher compared
to the cells with knockdown of miR-10b expression.
miR-10b mimics induced nearly complete wound
healing by 48 h, while the mnc group did not demon-
strate any healing at 72 h. miR-10b inhibitors or in-
hibitor negative control (inc) did not induce wound
healing at 72 h, but the inc group healed better com-
pared to the inhibitor group. These data indicate that
miR-10b overexpression promotes tumor cell viability
and migration (p < 0.01, Fig. 4c).
CSMD1 is a gene target of miR-10b in HCC cells
We next performed bioinformatics analyses using online
tools of TargetScan, PicTar, miRanda, RNAhybrid, or
DIANA-microT, and then identified two miR-10b binding
sites in the CSMD1 3’-UTR: 707–713 and 2158–2164.
pMIR-CSMD1-3’-UTR-WT contains both the 707–713
and 2158–2164 binding sites. pMIR-CSMD1-3’-UTR-
mut1 contains a mutation in the 707–713 (TGTCCCA)
site but the 2158–2164 site is normal; pMIR-CSMD1-3’-
UTR-mut2 contains a mutation in the 2158–2164
(TGTCCCA) site, but the 707–713 site is normal. We
therefore performed a luciferase reporter assay to confirm
the binding ability of miR-10b to CSMD1 cDNA and
found that miR-10b overexpression markedly suppressed
luciferase expression in HepG2 cells transfected with
pMIR-CSMD1-3’-UTR-WT but not pMIR-CSMD1-3’-
Fig. 3 Effects of miR-10b on HepG2 cell viability, colony formation, and apoptosis. HepG2 cells were transfected with hsa-miR-10b mimics (10b-m), mimics
negative control (mnc), hsa-miR-10b inhibitors (10b-i), inhibitors negative control (inc). a MTT assay. miR-10b mimics increased cell viability after 24–72 h of
transfection. In contrast, miR-10b inhibition reduced cell viability. b Colony formation and soft agar colony formation assay. miR-10b inhibitors reduced the
rate of colony formation by 17.5 and 4.25 %, respectively (p< 0.01). c Flow cytometry cell cycle assay. 19.3 % of miR-10b mimic-transfected cells were in
the S phase of the cell cycle, compared to only 8.02 % of negative control cells (p< 0.01). d Flow cytometry for apoptosis assessment. miR-10b transfected
cells exhibited lower rates of cell death (0.48 % of early apoptotic cells and 0.27 % of late apoptotic cells) compared to their negative control transfected
counterparts (1.24 % of early apoptotic cells, 1.24 and 0.91 % of late apoptotic cells; p< 0.01)
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UTR-mut1 (Fig. 5a). These results demonstrate that miR-
10b binds to the 707–713 site but not the 2158–2164 site
of the CSMD1 3’-UTR.
We next performed qRT-PCR and found that miR-10b
overexpression reduced CSMD1 expression, and con-
versely, knockdown of miR-10b resulted in increased
CSMD1 expression in cultured cells (p < 0.01, Fig. 5b).
Furthermore, CSMD1 expression was low in HepG2 com-
pared to normal liver cells (p < 0.01, Fig. 5c). As expected,
CSMD1 expression was higher in HepG2 cells transfected
with the miR-10b inhibitors, whereas CSMD1 expression
was reduced in HepG2 cells transfected with miR-10b
mimics (Fig. 5c, p < 0.01).
miR-10b promotes xenograft growth in nude mice
To further investigate the role of miR-10b in HCC
cells, we assessed its oncogenic activity in vivo. Usu-
ally, the in vivo half-life of miR-10b mimics is short;
thus, we used a miR-10b agomir, a synthetic modified
miR-10b analogue with a long in vivo half-life. The
data showed that miR-10b injection promoted growth
of tumor cell xenografts in nude mice (Fig. 6a). In-
deed, qRT-PCR data confirmed miR-10b expression in
xenografts (Fig. 6b). Moreover, we found that CSMD1
protein expression was decreased in xenografts com-
pared to mouse liver (Fig. 6c).
Downregulation of CSMD1 expression promotes HCC cell
proliferation, migration, and invasion
We then evaluated whether HCC cell growth is regulated
by CSMD1 expression. As shown in Fig. 7a, knockdown
of CSMD1 using siRNA reduced the expression of
CSMD1. Furthermore, knockdown of CSMD1 promoted
HepG2 cell proliferation (Fig. 7b). Importantly, HepG2
cell migration and invasion were also induced after
CSMD1 knockdown (Fig. 7c, d), suggesting that CSMD1
plays a functional role as a tumor suppressor gene.
Fig. 4 Effects of miR-10b on HCC cell migration and invasion. HepG2 cells were transfected with hsa-miR-10b mimics (10b-m), mimics negative control
(mnc), hsa-miR-10b inhibitors (10b-i), or inhibitors negative control (inc). a Transwell migration assay. miR-10b mimics led to a 2-fold increase in cell
migration, whereas knockdown of miR-10b reduced migration by 40 %. b Matrigel invasion assay. miR-10b mimics led to over 50 % increase in cell
invasion capacity, whereas knockdown of miR-10b reduced invasion by 40 %. c Wound healing assay. miR-10b mimics induced wound healing at
48 h, while the mnc group did not demonstrated wound healing at 72 h. miR-10b inhibitors and inc did not induce wound healing at 72 h, but the
inc group demonstrated better wound healing compared to the inhibitors
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Discussion
Aberrant miRNA expression in various human cancers
contributes to cancer development in different phases. miR-
NAs play an important role in regulating gene expression.
miR-10b is located in the HOX gene cluster on chromo-
some 2, suggesting that it is closely related to tumor inva-
sion and metastasis. Previous studies showed that miR-10b
was overexpressed in a variety of human cancers, such as
breast cancer, malignant glioma, nasopharyngeal carcin-
oma, pancreatic cancer, and HCC [10–14]. Consistent with
previous reports, our current study showed that miR-10b
was overexpressed in HCC tissue samples compared to ad-
jacent non-tumor tissues and in a HCC HepG2 cell line.
Up-regulation of miR-10b has been shown to promote in-
vasion and metastasis in breast cancer and esophageal can-
cer [14, 16]. In our current study, we found that miR-10b
also enhanced HepG2 cell migration and invasion in vitro.
Further, overexpression of miR-10b inhibited tumor cell
apoptosis. Taken together, our data are consistent with pre-
vious findings showing that miR-10b promotes HCC me-
tastasis [17], which suggests that miR-10b exerts oncogenic
activity in HCC.
miRNAs regulate expression of genes by binding to their
target mRNA and marking it for degradation or by blocking
protein translation. Generally, individual miRNAs regulate
multiple target genes, while several miRNAs can also regu-
late a single gene. Previous studies have shed light on the
relationship between miR-10b and cancer. Some studies
have revealed that miR-10b promotes metastasis of glioma
cells through regulation of HOXD10, Bim, TFAP2C, P16,
and P21 [13, 18]. Other studies have shown that miR-10b
induces invasion of breast cancer through targeting E-
cadherin, and Syndecan-1 [19, 20]. In HCC, miR-10b in-
duces cell invasion by modulating RhoC, uPAR, MMP-2,
and MMP-9 via HOXD10 [21]. Furthermore, CSMD1
participates in endothelial-to-mesenchymal transition
Fig. 5 miR-10b binds to CSMD1 3’-UTR and represses CSMD1 expression in HepG2 cells. a Luciferase activity assay. HepG2 cells were co-transfected
with pMIR/CSMD1 3’-UTR or mutated pMIR mu-CADM1 3’-UTR plus miR-10b mimics or negative control (NC). miR-10b overexpression markedly
suppressed luciferase expression in HepG2 cells transfected with pMIR-CSMD1-3’-UTR-WT but not pMIR-CSMD1-3’-UTR-mut1. b qRT-PCR. Expression of
CSMD1 mRNA after transfection with hsa-miR-10b mimics (10b-m) or hsa-miR-10b inhibitors (10b-i) was measured by qRT-PCR in HepG2. miR-10b
overexpression decreased CSMD1 expression; miR-10b knockdown increased CSMD1 expression in cultured cells c Immunocytochemistry. CSMD1
expression was low in HepG2 compared to normal liver HL-7702cells. d Immunocytochemistry. CSMD1 expression was higher in HepG2 cells transfected
with the miR-10b inhibitors, whereas CSMD1 expression was reduced in HepG2 cells transfected with miR-10b mimics
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(EndoMT), is a direct target of miR-10b [10, 22]. In our
study, we further explored the molecular mechanism
between miR-10b and CSMD1. Bioinformatics analyses
revealed that there are two binding sites for miR-10b in the
CSMD1 3’ UTR: 707–713 and 2158–2164. Luciferase
reporter assays showed that miR-10b could bind to the
707–713 site but not the 2158–2164 site.
CSMD1 is localized at chromosome 8p23.2 [23] and
allelic imbalance and chromosomal aberrations of
chromosome 8 are associated with development of many
cancers. Studies have shown that CSMD1 loss is a com-
mon phenomenon in breast, lung, prostate, and head
and neck cancers [24]. Similarly, Midorikawa et al.,
observed homozygous deletion and loss of heterozygos-
ity of 8p23.2 in HCC [25, 26]. Generally, homozygous
deletion is often related to tumor suppressor genes in
cancer. These findings suggest that CSMD1 is a putative
tumor suppressor gene. Surprisingly, homologous struc-
tures, namely the CUB and SUSHI domains, are shared
between CSMD1 and other proteins that play important
roles in cancer progression, such as SEZ6L and DMBT1
[27, 28]. Last but not least, low CSMD1 expression is
closely related to high tumor grade in a variety of can-
cers. Also, studies have shown that deletion of CSMD1
is associated with poor prognosis in head and neck squa-
mous cell carcinoma and prostate cancer [24, 29]. Taken
together, mounting evidence indicates that CSMD1
functions as a tumor suppressor gene.
In our previous study, we found that CSMD1 expres-
sion is lower in HCC, which is consistent with the re-
sults in breast cancer and melanoma [29, 30]. Compared
to normal liver cells, CSMD1 expression was downregu-
lated in HepG2 cells. We used siRNA-mediated silencing
of CSMD1 in order to further clarify the role of CSMD1
in tumor cell proliferation and invasion. Our findings
are consistent with previous observations regarding the
effects of miR-10b overexpression. Research has found
that CSMD1 can activate the Smad pathway to increase
antitumor activity [29]. Tumor growth factor-β (TGF-β)
activates this pathway in two ways via Smad2/3 and
Smad 1/5/8. Also, Morris et. al., reported that TGF-β
can promote hepatocarcinogenesis by inducing p53-
Fig. 6 Effects of miR-10b on regulation of tumor cell xenograft growth. miR-10b agomir or agomir negative control (NC) were injected into tumor
lesions. a miR-10b injection promoted xenograft growth in nude mice. b The relative levels of miR-10b expression in xenografts and nude mouse
liver tissues were measured by qRT-PCR. The expression level of miR-10b was significantly increased in tumor tissues compared to normal liver
tissues. c CSMD1 protein expression in xenografts and nude mouse livers was detected by immunohistochemistry. CSMD1 protein expression was
decreased in xenografts compared to mouse livers
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deficiency [31]. Some studies have demonstrated that
the TGF-β/Smad pathway can cause cell cycle arrest
through high expression p15, p21 and p27. These path-
ways may be associated with the tumor suppressor role
of CSMD1.
Conclusion
In conclusion, we analyzed miR-10b expression in HCC
tissue samples and investigated its effects on cells and
found that overexpression of miR-10b enhanced HCC
cell viability, migration, and invasion. Our study demon-
strates that CSMD1 is indeed a direct target of miR-10b
in HCC, and miR-10b can mediate an oncogenic effect
in HCC by targeting CSMD1. These findings provide
important information toward the goal of developing
miR-10b and CSMD1 as promising candidates for effect-
ive HCC therapeutic strategies.
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Fig. 7 Effects of CSMD1 knockdown on tumor cell viability, invasion, and migration. HepG2 cells were transfected with CSMD1 siRNA or NC a
CSMD1 protein levels were decreased in HepG2 cells transfected with CSMD1 siRNA. b MTT assay. Knockdown of CSMD1 using siRNA promoted
proliferation in HepG2 cells. c Transwell migration assay. Knockdown of CSMD1 promoted migration in HepG2 cells. d Matrigel invasion assay.
Knockdown of CSMD1 expression enhanced invasion of HepG2 cells
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